| Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade IG House, P Savas, J Lai, AXY Chen, AJ Oliver, ZL Teo, KL Todd, ... Clinical Cancer Research 26 (2), 487-504, 2020 | 416 | 2020 |
| Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy PA Beavis, MA Henderson, L Giuffrida, JK Mills, K Sek, RS Cross, ... The Journal of clinical investigation 127 (3), 929-941, 2017 | 293 | 2017 |
| CAR T cells for acute myeloid leukemia: state of the art and future directions S Mardiana, S Gill Frontiers in oncology 10, 697, 2020 | 172 | 2020 |
| Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity J Lai, S Mardiana, IG House, K Sek, MA Henderson, L Giuffrida, ... Nature immunology 21 (8), 914-926, 2020 | 135 | 2020 |
| CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy L Giuffrida, K Sek, MA Henderson, J Lai, AXY Chen, D Meyran, KL Todd, ... Nature communications 12 (1), 3236, 2021 | 118 | 2021 |
| Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression S Mardiana, BJ Solomon, PK Darcy, PA Beavis Science translational medicine 11 (495), eaaw2293, 2019 | 115 | 2019 |
| Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting CY Slaney, B Von Scheidt, AJ Davenport, PA Beavis, JA Westwood, ... Clinical cancer research 23 (10), 2478-2490, 2017 | 112 | 2017 |
| A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cells S Mardiana, LB John, MA Henderson, CY Slaney, B von Scheidt, ... Cancer research 77 (6), 1296-1309, 2017 | 69 | 2017 |
| IL-15 preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors L Giuffrida, K Sek, MA Henderson, IG House, J Lai, AXY Chen, KL Todd, ... Molecular Therapy 28 (11), 2379-2393, 2020 | 64 | 2020 |
| Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3− Cell–Mediated Modulation of CD103+ Dendritic Cells PA Beavis, MA Henderson, L Giuffrida, AJ Davenport, EV Petley, ... Cancer immunology research 6 (9), 1069-1081, 2018 | 60 | 2018 |
| Tissue‐specific tumor microenvironments influence responses to immunotherapies AJ Oliver, AS Davey, SP Keam, S Mardiana, JD Chan, B von Scheidt, ... Clinical & translational immunology 8 (11), e1094, 2019 | 27 | 2019 |
| Switching on the green light for chimeric antigen receptor T‐cell therapy S Mardiana, J Lai, IG House, PA Beavis, PK Darcy Clinical & Translational Immunology 8 (5), e1046, 2019 | 12 | 2019 |
| Repurposing bi-specific chimeric antigen receptor (CAR) approach to enhance CAR T cell activity against low antigen density tumors S Mardiana, O Shestova, M Ruella, S Gill Blood 136, 30, 2020 | 2 | 2020 |
| Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors P Darcy, K Sek, A Chen, T Cole, J Armitage, J Tong, KM Yap, I Munoz, ... | | 2024 |
| Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors S Mardiana, O Shestova, SA Grupp, M Ruella, DM Barrett, S Gill Blood 138, 1727, 2021 | | 2021 |
| Novel strategies to enhance the therapeutic efficacy of chimeric antigen receptor T cell therapy against solid cancer S Mardiana Centre for Cancer Research, 2018 | | 2018 |
